Misplaced Pages

This is an old revision of this page, as edited by Whywhenwhohow (talk | contribs) at 20:20, 10 June 2022 (MOS:DATED). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Apolizumab is a humanized monoclonal antibody intended for use in hematologic cancers. Development was abandoned in 2005, because of toxic effects and lack of efficacy in humans. The observed dose limiting toxic effects were aseptic meningitis and hemolytic uremia.

References

1. Bayes M; Rabasseda X; Prous J (2003). "Gateways to clinical trials". Methods Find Exp Clin Pharmacol. 25 (9): 747–71. PMID 14685303.
2. Rech, J; Repp, R; Rech, D; Stockmeyer, B; Dechant, M; Niedobitek, G; Gramatzki, M; Valerius, T (2006). "A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study". Leukemia & Lymphoma. 47 (10): 2147–54. doi:10.1080/10428190600757944. PMID 17071489. S2CID 24080973.
3. Lin TS, Stock W, Xu H, Phelps MA, Lucas MS, Guster SK, Briggs BR, Cheney C, Porcu P, Flinn IW, Grever MR, Dalton JT, Byrd JC (December 2009). "A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia". Leuk. Lymphoma. 50 (12): 1958–63. doi:10.3109/10428190903186486. PMC 8166408. PMID 19860603. S2CID 22328921.

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Drugs not assigned an ATC code
• Monoclonal antibodies
• Abandoned drugs
• Monoclonal antibody stubs
• Antineoplastic and immunomodulating drug stubs